Live Feeds
● LIVE Updated 1h ago · 13 sources tracked

Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma

Novartis has confirmed nine reported instances of tumors in patients treated with its spinal muscular atrophy gene therapy, Zolgensma. Among these cases, seven were newly disclosed, and two included evidence that the viral delivery vector integrated into patient DNA near the GLI1 oncogene. While advocates sound alarms on social media after learning details from doctors, the US Food and Drug Administration continues to investigate the malignancy risk associated with the treatment, even as its product label still labels the risk as theoretical.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (13)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novartis confirmed nine reported cases of tumors in patients treated with the spinal muscular atrophy gene therapy Zolgensma.
  • ✓ Seven of the nine tumor instances were newly disclosed by Novartis.
  • ✓ Two of the reported cases involved evidence that the gene therapy vector integrated into patient DNA near the GLI1 oncogene.
  • ✓ The Food and Drug Administration is investigating the malignancy risk associated with Zolgensma.
🛡️ Source Corroboration: 13 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Novartis disclosed seven new tumor cases alongside two previously known instances involving vector integration.

Live updates

  1. Novartis Confirms Nine Tumor Reports Linked to Zolgensma

    Novartis has confirmed nine reported instances of tumors in patients treated with its spinal muscular atrophy gene therapy, Zolgensma. Among these cases, seven were newly disclosed, and two included evidence that the viral delivery vector integrated into patient DNA near the GLI1 oncogene. While advocates sound alarms on social media after learning details from doctors, the US Food and Drug Administration continues to investigate the malignancy risk associated with the treatment, even as its product label still labels the risk as theoretical.

    Why it matters

    Zolgensma is a prominent gene therapy designed to treat spinal muscular atrophy by delivering functional genes via a viral vector. The identification of insertional oncogenesis in these patients raises critical questions for the broader gene therapy field regarding DNA integration and long-term safety. Regulatory bodies and clinicians are closely monitoring the situation as patient advocates push for greater transparency.

    What is confirmed

    • Novartis confirmed nine reported cases of tumors in patients treated with the spinal muscular atrophy gene therapy Zolgensma.
    • Seven of the nine tumor instances were newly disclosed by Novartis.
    • Two of the reported cases involved evidence that the gene therapy vector integrated into patient DNA near the GLI1 oncogene.
    • The Food and Drug Administration is investigating the malignancy risk associated with Zolgensma.

    What to watch next

    • Updates from the Food and Drug Administration regarding its ongoing investigation into Zolgensma malignancy risks
    • Potential changes to the Zolgensma product label concerning insertional oncogenesis and tumor risks
    Sources used for this update (14)
    1. www.yahoo.com — Yahoo
    2. www.biospace.com — GSK restructure will hit home, impacting 'limited' UK roles
    3. BioSpace — Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
    4. FirstWord Pharma — Novartis faces questions over tumours reported after Zolgensma treatment
    5. Tech Times — Novartis Confirms Zolgensma Caused Tumors in Two Children Via Gene Therapy Vector Integration
    6. www.biospace.com — Novartis confirms 9 reported cases of tumors in patients ...
    7. www.genengnews.com — Novartis Confirms Nine Cases of Tumors in Children Treated ...
    8. www.newsbreak.com — Novartis confirms 9 reported cases of tumors in patients ...
    9. www.techtimes.com — Novartis Confirms Zolgensma Caused Tumors in Two Children Via ...
    10. www.medicaldaily.com — Novartis Confirms Nine Tumor Reports After Zolgensma Gene ...
    11. www.biopharmadive.com — Novartis reveals cancer cases possibly linked to gene therapy Zolgensma | BioPharma Dive
    12. www.cancernetwork.com — Silevertinib Shows Robust CNS Activity in EGFR-Mutated NSCLC Trial
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community